AstraZeneca turnaround is 3-4 year journey, says CEO

Your Health Matters

CEO of AstraZeneca, Pascal Soriot, poses for a photograph in this undated picture provided by AstraZeneca in LondonBy Ben Hirschler LONDON (Reuters) – Turning around drugmaker AstraZeneca will be a long haul, with a strategy of revamping research and boosting acquisitions set to take up to four years to pay off, its chief executive said on Tuesday. Speaking as the group unveiled the location for a new global headquarters and research center in Cambridge, England, Pascal Soriot said he was not expecting any short-term fixes for the group, which is struggling from falling sales as patents expire. …

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave